BACILLUS CLAUSII EG

Informazioni principali

  • Nome commerciale:
  • BACILLUS CLAUSII EG 10FL 2MLD
  • Forma farmaceutica:
  • SOSPENSIONE OS
  • Composizione:
  • " 2 MLD/5 ML SOSPENSIONE ORALE" 10 CONTENITORI MONODOSE
  • Classe:
  • C
  • Tipo di ricetta:
  • Senza obbligo di ricetta
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco allopatico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • BACILLUS CLAUSII EG 10FL 2MLD
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Antidiarrheal microorganisms

Altre informazioni

Status

  • Fonte:
  • AIFA - Agenzia Italiana del Farmaco
  • Numero dell'autorizzazione:
  • 028939039
  • Ultimo aggiornamento:
  • 09-08-2016

Foglio illustrativo

CATEGORIA FARMACOTERAPEUTICA

Sospensione di microrganismi antidiarroici.

INDICAZIONI

Trattamento degli stati di dismicrobismo intestinale e delle sue

manifestazioni cliniche specie nei lattanti (ad es. diarrea).

Terapia coadiuvante il ripristino della flora microbica

intestinale, alterata nel corso di trattamenti antibiotici o

chemioterapici.

CONTROINDICAZIONI/EFFETTI SECONDARI

Il prodotto non deve essere usato in caso di ipersensibilita' ai

suoicomponenti.

Non esistono controindicazioni all'uso del prodotto in gravidanza

e durante l'allattamento.

POSOLOGIA

Adulti: 2 - 3 contenitori monodose al giorno.

Bambini e lattanti: 1 -2 contenitori monodose al giorno.

Somministrare ad intervalli regolari(3 - 4 ore), diluendo il

contenuto in acqua, latte, te', aranciata.

INTERAZIONI

Nessuno.

EFFETTI INDESIDERATI

Non sono stati segnalati a tutt'oggi effetti indesiderati con

l'impiego del farmaco.

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of a strain of Lactobacillus hilgardii and of Lactobacillus buchneri when used as a technological additive intended to improve ensiling at a proposed application rate of 3.0 x 108 colony forming units (CFU)/kg fresh material. The two bacterial species are considered by EFS...

Europe - EFSA - European Food Safety Authority Publications

30-8-2018

Anthrax

Anthrax

Anthrax is a zoonosis (i.e. a disease common to humans and animals) that primarily affects herbivores. It is caused by Bacillus anthracis, a bacterium that is unusual in that it persists in soil for decades as spores. ANSES is the National Reference Laboratory for this disease. Here we provide a presentation of the disease and the role played by ANSES.

France - Agence Nationale du Médicament Vétérinaire

25-5-2018

Nosocomial infections can also be caused by the Bacillus cereus bacterium

Nosocomial infections can also be caused by the Bacillus cereus bacterium

While Bacillus cereus is well known as a source of food infections, researchers from INRA and ANSES, working with doctors at nine French hospitals[1] including those in the Paris Public Hospital System (AP-HP), have demonstrated for the first time that this bacterium is also responsible for inter- and intra-hospital nosocomial contamination.

France - Agence Nationale du Médicament Vétérinaire

Non ci sono notizie relative a questo prodotto.